Lilly, Biogen and more gear up for blockbuster launches in 2023: report

With many of the world’s top-selling drugs speeding toward patent expirations over the next few years, pharmaceutical companies are hurrying to identify replacements.

In its 11th annual list of Drugs to Watch, data analytics company Clarivate highlights 15 that were launched in the U.S. last year or are likely to be approved in 2023.